A Parallel-arm, Double-blind, Placebo and Positive Controlled Multiple Oral Dose Administration Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder.

Trial Profile

A Parallel-arm, Double-blind, Placebo and Positive Controlled Multiple Oral Dose Administration Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2015

At a glance

  • Drugs Brexpiprazole (Primary) ; Moxifloxacin
  • Indications Bacterial infections; Schizoaffective disorder; Schizophrenia
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 10 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Apr 2012 Actual patients number is 218 as reported by ClinicalTrials.gov.
    • 12 Jan 2012 Planned end date changed from 1 Feb 2012 to 1 Mar 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top